At Parexel, we understand that embracing diversity, equity and inclusion (DEI) is not just the right thing to do — it's essential to driving innovation and serving our global community effectively. 🌍✨ Through employee-led committees, Patient Advisory Councils, robust DEI training and a diverse workforce that reflects the patients we serve, we're setting standards across our industry. By fostering an environment where unique perspectives thrive, we're not just improving outcomes for patients—we're also creating a workplace where everyone can succeed and contribute to our mission. Learn how we're integrating DEI in everything we do at Parexel: https://insde.co/g7g0
About us
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.
- Website
-
http://www.parexel.com
External link for Parexel
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Specialties
- Regulatory and product development consulting, early phase clinical research, phase II-III clinical research, late phase clinical research, eClinical solutions, patient and site recruitment, medical device consulting, clinical research organization, pharmacovigilance, biotechnology, biotech, and market access
Locations
-
Primary
2520 Meridian Pkwy
Durham, North Carolina 27713, US
Employees at Parexel
Updates
-
We strive to design and deliver clinical trials with patients in mind, making clinical research a care option for anyone, anywhere. By tapping into real-world patient insights, we’re able to include diverse patients, design trials that meet their needs, and yield effective drugs that work across populations. We are excited to announce that Chief Patient Officer Stacy Hurt 🌻 will lead our on-site team at the #CPOSummit in Boston! Stacy will present with patient advocacy leaders on the latest approaches to improving trial experiences and the meaningful benefits this commitment offers both patients and drug developers. Drop a comment below about what you are looking forward to hearing about 👇 Schedule a meeting with our team at the event or learn more about our participation here: https://lnkd.in/dvvQ9PSs #PatientsFirst #PatientAdvocacy #PatientInsights #ClinicalTrials
-
Tune in to Episode 2 of ACRO's Good Clinical Podcast, where Stephen Pyke and the FDA's Dr. Tala Fakhouri discuss the massive potential of AI in clinical research. 🎙 Learn more about the FDA's evidentiary standards for AI, the importance of methodological transparency in submissions and how AI stands to streamline the drug development process, helping to bring life-changing medicines to market more efficiently. 💡 Stephen also sheds light on where AI advancements will show up and what it means for patients. 👇 Watch below! Don’t miss this fascinating discussion. Access the full episode here: https://lnkd.in/gdMz_agR #ACRO #GoodClinicalPodcast #ArtificialIntelligence
-
Accelerating clinical trials takes on special urgency in oncology. Martin Roessner explains how Parexel Biotech is advancing innovative approaches to optimize study design and streamline protocols. He shares that the more flexible the study, the more complex it is. However, even in the case of a biotech company with limited capital, a flexible trial design could confirm efficacy and safety as an early milestone and potentially lead to a second round of financing. Read the full article and be sure to follow the rest of this oncology blog series: https://lnkd.in/gRPwG6EE Learn more about how our dedicated team of Biotech experts will amplify your team's expertise to help you uncover insights faster. #ClinicalResearch #Biotech #Innovation #Oncology #ParexelBiotech
-
The analysis of large published literature to gather safety and efficacy information on medical products is critical for compliance and patient safety. This week, we spoke with Pallavi Rehal, Director of Pharmacovigilance Operations at Parexel, about how #AI is supporting her team’s efforts in safety services. Click through to read her opinions on artificial intelligence in clinical research in the latest edition of our #AIandMe series. Share your experiences below! #Pharmacovigilance #ArtificialIntelligence #MachineLearning #DrugSafety
-
Chief Patient Officer Stacy Hurt 🌻joined Alicia C. Staley of Medidata Solutions to kick off Season 2 of ACRO's Good Clinical Podcast with Sophia McLeod! 🎧 Tune in to hear how Stacy’s experiences as a patient and caregiver have shaped her perspective on the vital role of the patient voice in reducing burden and turning buzz words into action! 💪 https://lnkd.in/gdMz_agR
-
Are biomarkers the key to diagnosing and treating cancer effectively? 🔑 They help identify patients who will benefit most from targeted therapies, making clinical trials faster and more efficient. However, reliable biomarkers are still lacking for many cancers. 🔎 At Parexel, our team of experts is leveraging diverse data streams and exciting advances in #AI and #machinelearning to fast-track cancer research and improve patient outcomes. We asked Angela Qu to describe how recent advances in multi-omics and computational analytics accelerate the discovery and validation of biomarkers in precision oncology. Read her responses here: https://lnkd.in/g2RPNWNS #Biomarkers #Oncology #PrecisionOncology #NovelInsights
-
Over the past three years, Parexel and Veeva Systems have collaborated to accelerate clinical trials through Veeva’s suite of technology applications, including Veeva Vault eTMF, Vault CTMS, Veeva EDC and Vault Study Startup. Together we've streamlined trial processes, created efficiencies and made clinical trial participation easier for all. 💪 Parexel colleagues connected recently with the Veeva team to discuss ways to further enhance the clinical trials experience for participants, patients and site professionals. Exciting times ahead as we continue to innovate and transform clinical research! #Veeva #ClinicalTrials #Collaboration
-
Parexel reposted this
Let's talk about the long-awaited update to the FDA guidelines on diversifying patient enrollment... #parexel #ACRO #withheart #patientsfirst #FDA #allpatients
-
The potential of human gene editing to change the lives of those with genetic diseases cannot be understated. 🧬 In response to substantial growth in the development of therapies utilizing these technologies, the FDA released draft guidance earlier this year. 📝 In this edition of the New Medicines, Novel Insights newsletter, regulatory experts at Parexel discuss key takeaways from the FDA’s guidance on nonclinical assessment and identify important considerations for future gene editing product development. Discover more about the nonclinical studies and other requirements to support a successful IND submission for an investigational product. Read the full article below and subscribe to stay updated on the latest #NovelInsights from our bi-weekly clinical research newsletter! #FDA #Regulatory #GeneEditing
Key implications for nonclinical development: FDA guidance on human gene therapy products incorporating human genome editing
Parexel on LinkedIn